financial statements 149 Hikma PHarmaceuticals Plc annual report 2011 45. due from subsidiaries Continued 2011 2010 current assets $000 $000 due from hikma pharma limited jersey 7,222 7,221 due from hikma farmaceutica portugal 487 165 due from hikma pharma germany 78 86 due from hikma uk limited 93,446 94,723 due from hikma limited 580 307 due from hikma mena holdings limited 7,151 due from west-ward pharmaceutical corp. 1,196 others 1,506 971 111,666 103,473 46. financial assets cash and cash equivalents these comprise cash held by the company and short-term bank deposits with an original maturity of three months or less.
the carrying amount of these assets approximates to their fair value.
47. financial liabilities other payables the Directors consider that the carrying amount of other payables approximates to their fair value.
48. due to subsidiaries Due to subsidiaries mainly represents an amount due to Hikma Holdings uk ltd which is a non interest-bearing loan repayable on demand.
49. long-term financial debts the company has entered into a seven year syndicated term loan of up to usD 180,000,000 which was entered into on 27 september 2011. theloan has an outstanding balance at year end of usD 140,000,000 with a fair value of usD 137,400,000 and a zero unused available limit.
the syndicated loan has been underwritten by usD 140,000,000. as of the balance sheet date the syndicate was not closed.
Quarterly repayments for the term loan should commence 18 months after the date of the agreement and will continue until the 84th month after thedateof the agreement.
Payment will be made with equal installments representing 3.182% from the loan balance and a bullet payment of30% at the maturity of the loan.
the loan has been used to finance the Promopharm acquisition and general Group capital expenditures.
